New Strong Sell Stocks for May 29th

Zacks has added Corcept Therapeutics (CORT), Arc Resources (AETUF), and AG Mortgage Investment Trust (MITT) to its Rank #5 (Strong Sell) list, citing downward revisions to current year earnings estimates of 21.4%, 20.8%, and 17.5% respectively over the last 60 days; separately, Zacks' Director of Research highlighted one stock, among a group of five, with the greatest probability of gaining +100% or more in the coming months.

Analysis

Zacks Investment Research has designated Corcept Therapeutics (CORT), Arc Resources (AETUF), and AG Mortgage Investment Trust (MITT) as Rank #5 (Strong Sell) stocks. This classification is primarily driven by significant downward revisions in their respective Zacks Consensus Estimates for current year earnings over the past 60 days. Specifically, Corcept Therapeutics, a company focused on drugs for severe metabolic, psychiatric, and oncology disorders, saw its earnings estimate revised downward by nearly 21.4%. Arc Resources, an oil and natural gas exploration and development firm in western Canada, experienced a 20.8% downward revision. AG Mortgage Investment Trust, a REIT specializing in residential mortgage assets, had its earnings estimate reduced by 17.5%. These substantial revisions indicate a deteriorating earnings outlook for these companies as perceived by analysts. The per-ticker sentiment scores corroborate this negative outlook, with CORT and AETUF at -0.8 and MITT at -0.7, reflecting strong negative sentiment. The article's overall sentiment is mixed due to a separate mention of a Zacks top pick poised for significant gains, though details on this specific stock are not provided in the context of the sell-rated entities. The identified themes of "Analyst Estimates" and "Company Fundamentals" are central to these rating changes.

Key Decisions for Investors

• Investors holding or considering positions in Corcept Therapeutics (CORT), Arc Resources (AETUF), or AG Mortgage Investment Trust (MITT) should exercise caution given the Zacks Rank #5 (Strong Sell) rating and the substantial recent downward revisions in current year earnings estimates.
• It is advisable to closely monitor upcoming earnings reports and any further analyst estimate revisions for these three companies to assess if the negative trend persists or reverses.
• Consider reviewing portfolio allocations to these specific stocks, particularly if a positive earnings trajectory was a key investment thesis, as the current outlook suggests underperformance.